Base de dados : LILACS
Pesquisa : D20.215.894.135 [Categoria DeCS]
Referências encontradas : 159 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 16 ir para página                         

  1 / 159 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-884680
Autor: Leguizamón, Rosa; Guillén, María Cristina; Vega Bogado, María Enilda; Gómez, Gloria.
Título: Meningitis en el Hospital Nacional: VI muestra nacional de epidemiología / Meningitis in the National Hospital: VI national epidemiological sample
Fonte: Rev. Nac. (Itauguá);9(1):61-77, jun 2017.
Idioma: es.
Resumo: Introducción: las meningitis constituyen un importante problema de Salud Pública, que afectan de manera especial a los niños menores de 5 años. La etiología más frecuente es viral. Desde la introducción de la vacuna conjugada contra H. influenzae tipo b, S. pneumoniae y N. meningitidis los virus pasaron a ser los agentes más frecuentes. A nivel país, en 2014 y 2015, la etiología viral fue la más frecuente con valores de 69% y 77%, respectivamente, atribuyéndose a las bacterianas como segunda causa. Objetivos: describir las características epidemiológicas de las meningitis, en pacientes de todas las edades internados en el lapso de enero del 2014 a octubre del 2015 en el Hospital Nacional de Itauguá, Paraguay. Metodología: estudio epidemiológico, descriptivo, transversal. Se incluye a pacientes de todas las edades que ingresaron con sospecha de meningitis y/o encefalitis en el periodo de estudio. Resultados: en el periodo de estudio ingresaron 173 casos probables de 201 casos sospechosos de meningitis correspondiendo al 0,5% (173/35140) de todos los ingresos hospitalarios. El grupo etario más afectado fue el de menores de 5 años y entre los mayores de 5 años el de 5 a 14 años. En el 53% procedieron del Departamento Central. Los cuadros clínicos fueron: 98 casos (57%) encefalitis viral, meningitis bacteriana aguda 65 casos (37%), 7 casos (4%) meningitis micótica (Criptococcus). Fallecieron 3 casos de encefalitis y 9 casos de meningitis bacteriana aguda. De 25 casos en edad de vacunarse, 52 % se vacunaron para H. influenzae b y 16% contra P. pneumoniae. No se ha registrado vacunación para N. meningitis en ningún caso. Conclusiones: la incidencia total de meningitis en este periodo de estudio fue de 173 casos. Más de la mitad de los casos fueron de etiología viral. La bacteria más frecuentemente identificada fue S. pneumoniae. En general el grupo de edad más afectado fue el de menores de 5 años. La letalidad fue de 3% en los casos de encefalitis viral, 14% en meningitis bacteriana aguda y 43% en meningitis a Criptococcus. Se desconoce el estado de vacunación de casi la mitad de los casos sobre todo de la antineumocóccica.

Introduction: Meningitis is an important public health problem, which affects children under 5 years of age. The most frequent etiology is viral. Since the introduction of the conjugate vaccine against H. b, S. pneumoniae and N. meningitidis, they became the most frequent agents. In the hole country, in 2014 and 2015, the viral etiology was the most frequent with values ​​of 69% and 77%, respectively, being attributed to the bacterial ones as the second cause. Objectives: To know the epidemiological characteristics of meningitis in all ages hospitalized patients from January 2014 to October 2015 at the National Hospital of Itaugua, Paraguay. Methodology: Epidemiological, descriptive, cross-sectional study. Patients of all ages admitted with suspected meningitis and / or encephalitis were included in the study. Results: During the study, 173 probable cases of 201 suspected cases of meningitis corresponding to 0.5% (173/35140) of all hospital admissions were registered. The more affected age group was the group of children under 5 and among patients with more than 5 years, were between 5 to 14 years; In 53%, they came from the central department.98 cases (57%) were viral encephalitis; Acute bacterial meningitis 65 cases (37%); 7 cases (4%) Fungal Meningitis (Cryptococcus). Of 41 confirmed viral cases (42%), 29 cases (71%) were by Enterovirus. 18 cases of MBA were confirmed; S.pneumoniae (8) or Spn, S were identified. Aureus (4), N.meningitidis (2) or NmStreptococcus group B (1), E. coli (1), S. Epidermidis MR (1) and S. agalactiae (1); From 5 Spn the sero types / serogroups were identified: 6C / 6D (1), serotype14 (1), serotype3 (1), NmW 135 (1), Nmsero group B (1) in a young adult case. There were 3 cases of encephalitis and 9 cases of MBA. Twenty-five cases were vaccinated for Hib and 16% were vaccinated against P.pneumoniae; No vaccination has been registered for Nm. Conclusions: The total incidence of meningitis in this period of study was 173 cases. More than half of the cases were of viral etiology; The most frequently identified bacterium was S. pneumoniae. In general, the most affected age group was children under 5 years of age. The majority coming from the Central department and Cordillera. The lethality was 3% in cases of viral encephalitis; 14% in MBA and 43% in Cryptococcus meningitis. It is unknown the vaccination status of almost half of the cases especially of the anti pneumococcal.
Descritores: Meningite/epidemiologia
-Vacinas Bacterianas/uso terapêutico
Doença Aguda
Estudos Transversais
Meningites Bacterianas/epidemiologia
Encefalite Viral/epidemiologia
Meningite Viral/epidemiologia
Limites: Seres Humanos
Masculino
Feminino
Recém-Nascido
Lactente
Pré-Escolar
Criança
Adolescente
Adulto
Meia-Idade
Adulto Jovem
Responsável: BR1.1 - BIREME


  2 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Morais, Zenaide Maria de
Vasconcellos, Silvio Arruda
Texto completo
Id: biblio-889235
Autor: Sonada, Rafael Bazaglia; Azevedo, Sérgio Santos de; Soto, Francisco Rafael Martins; Costa, Diego Figueiredo da; Morais, Zenaide Maria de; Souza, Gisele Oliveira de; Gonçales, Amane Paldês; Miraglia, Fabiana; Vasconcellos, Sílvio Arruda.
Título: Efficacy of leptospiral commercial vaccines on the protection against an autochtonous strain recovered in Brazil
Fonte: Braz. j. microbiol;49(2):347-350, Apr.-June 2018. tab.
Idioma: en.
Projeto: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Resumo: Abstract In swine and bovines, leptospirosis prevention and control is carried out via vaccination of susceptible animals using bacterins. However, the efficiency of leptospirosis vaccines has been questioned. This work aimed to investigate the potency of five leptospirosis vaccines sold commercially in Brazil, challenging the animals with one autochthonous strain of Leptospira, Canicola serovar, denoted LO4, isolated from swine. The standard protocol was followed, and renal carriers of Leptospira were identified among the surviving animals by culture and PCR. Of the five vaccines tested, only two proved effective. None of the surviving animals was positive by culture; however, one animal was positive by PCR. Three of the five vaccines sold commercially in Brazil for the immunization of swine or bovines failed the test of the efficacy to protect the vaccinated animals following challenge with an autochthonous Leptospira strain, Canicola serovar. The two vaccines provided protection against the renal carrier state in the surviving animals. The criteria used to produce leptospirosis bacterins sold commercially in Brazil must be reviewed. The industry should support researches on leptospiral vaccinology to improve the quality of the present vaccines and discover new immunogenic strains, because it is known that vaccination is one of the most important tools to increase the reproduction rates in livestock.
Descritores: Doenças dos Suínos/prevenção & controle
Vacinas Bacterianas/administração & dosagem
Vacinas Bacterianas/imunologia
Doenças dos Bovinos/prevenção & controle
Leptospira/imunologia
Leptospirose/veterinária
-Suínos
Doenças dos Suínos/patologia
Brasil
Doenças dos Bovinos/patologia
Análise de Sobrevida
Resultado do Tratamento
Rim/microbiologia
Leptospira/isolamento & purificação
Leptospirose/patologia
Leptospirose/prevenção & controle
Limites: Animais
Bovinos
Responsável: BR1.1 - BIREME


  3 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-889201
Autor: Siqueira, Franciele Maboni; Cibulski, Samuel Paulo; Mayer, Fabiana Quoos; Driemeier, David; Pavarini, Saulo Petinatti; Vargas, Agueda Palmira Castagna de.
Título: Genome sequencing of two Bacillus anthracis strains: a virulent strain and a vaccinal strain
Fonte: Braz. j. microbiol;49(1):18-19, Jan.-Mar. 2018.
Idioma: en.
Projeto: Universidade Federal de Santa Maria.
Resumo: ABSTRACT Bacillus anthracis strain SPV842_15 was isolated from bovine fetus, while B. anthracis strain Brazilian vaccinal was recovered from a commercial vaccine. We report here the genome sequences of both strains. The SPV842_15 genome is composed of a single circular chromosome with a length of 5,228,664 base pairs, and comprises 5911 coding sequences. In turn, the Brazilian vaccinal genome remains in 201 contigs with 5733 coding sequences. Both genomes have an overall C + G content of 35.4%, and 11 genes encoding the ribosomal RNAs (rRNAs) 5S, 16S and 23S. Only the plasmid pX01 sequence, which carries genes for toxins synthesis, was detected and completely assembled for both strains. These plasmids have a length of 181,684 base pairs and a C + G content of 32.5%. These genomic data generate insights about vaccinal B. anthracis virulence.
Descritores: Bacillus anthracis/isolamento & purificação
Bacillus anthracis/genética
Vacinas Bacterianas/genética
Doenças dos Bovinos/microbiologia
Genoma Bacteriano
-Filogenia
Plasmídeos/genética
Bacillus anthracis/classificação
Composição de Bases
DNA Bacteriano/genética
Dados de Sequência Molecular
Vacinas Bacterianas/isolamento & purificação
Sequência de Bases
Limites: Animais
Bovinos
Responsável: BR1.1 - BIREME


  4 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-230782
Autor: Medeiros, Lucas Alberto.
Título: Dosagem de níveis de anticorpos contra polissacarídeos capsulares de Streptococcus pneumoniae após vacinaçäo de pacientes HIV positivos com vacina pneumocócica 23-valente / Quantification of antibody levels anti-Streptococcus pneumoniae capsular polysaccharide in HIV-infected patients after vaccination with the 23-valent vaccine.
Fonte: Säo Paulo; s.n; 1998. 123 p.
Idioma: pt.
Tese: Apresentada a Universidade de Säo Paulo. Instituto de Ciências Biomédicas para obtenção do grau de Mestre.
Resumo: Streptococcus pneumoniae é o agente causal mais comum de pneumonias bacterianas e bacteremias nao micobacterianas em indivíduos infectados pelo HIV, estimando-se que esses pacientes sejam de 100 a 300 vezes mais susceptíveis à doença pneumocóccica invasiva, se comparados a indivíduos nao infectados pelo HIV. Desde 1989 o Centers for Disease Control and Prevention, EUA indica a vacina pneumocócia 23-valente na populaçao HIV+. No entanto, vários estudos encontraram uma resposta diminuída à vacinaçao nesta populaçao, principalmente nos indivíduos imunossuprimidos. Em contrapartida, outros estudos observaram respostas semelhantes aos controles normais, sendo sua indicaçao ainda polêmica. Realizamos a dosagem de anticorpos contra polissacarídeos capsulares de Streptococcus pneumoniae sorotipos 1, 3, 5, 6B, 9V e 14 antes e após imunizaçao com vacina pneumocócica 23-valente de 15 indivíduos voluntários normais HIV-e de 42 indivíduos HIV+, distribuídos em três grupos pela contagem de LTCD4+ (Grupo I > 500 células/mm3, Grupo II entre 200 e 499 células/mm3 e Grupo III < 200 células/mm3). Observamos que os títulos de anticorpos contra os polissacarídeos capsulares do Streptococcus pneumoniae, antes da vacinaçao, sao semelhante entre os indivíduos normais e os portadores do vírus HIV, independentemente do grau de imunodepressao. Verificamos também que a resposta à imunizaçao com a vacina pneumocócica 23-valente, aos antígenos capsulares dos sorotipos testados, é semelhante entre os controles normais e os indivíduos HIV+, mesmo nos pacientes com LTCD4+ < 200 céls/mm3, independentemente do uso de anti-retrovirais. Nenhum dos grupos respondeu de forma adequada, ao sorotipo 3; o sorotipo que induziu a melhor resposta em todos os grupos foi o 14.
Descritores: Polissacarídeos Bacterianos/imunologia
Streptococcus pneumoniae/imunologia
Vacinas Bacterianas/administração & dosagem
Vacinas Bacterianas/imunologia
Anticorpos Antibacterianos/análise
Infecções por HIV
Pneumonia Pneumocócica/prevenção & controle
Limites: Seres Humanos
Masculino
Feminino
Adulto
Meia-Idade
Responsável: BR1.1 - BIREME
BR1.1; 3265.00; BR32.1; T-ICB BMI QW504 M488d 1998


  5 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-339434
Autor: Barsanti, Cláudio; Barsanti, Márcia.
Título: Imunização contra doença meningocócica / Imunization against meningococcal disease
Fonte: Pediatr. mod;36(5):275:278:280-276-278-280, maio 2000.
Idioma: pt.
Descritores: Vacinas Bacterianas
Neisseria meningitidis
Infecções Meningocócicas/epidemiologia
Infecções Meningocócicas/prevenção & controle
Meningite Meningocócica/epidemiologia
Vacinação
Limites: Seres Humanos
Lactente
Pré-Escolar
Criança
Adolescente
Responsável: BR11.1 - Biblioteca


  6 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-263135
Autor: Ávila, Carlos Armando de; Pannuti, Cláudio Sérgio; Tsukumo, Marina Keiko K; Malaman, Sérgio Antônio; Moraes, Vera Maria C. de.
Título: Vacinação contra doença meningocócica / Vaccination against meningococcal disease
Fonte: Pediatr. mod;35(1/2):39, 41-2, jan.-fev. 1999.
Idioma: pt.
Descritores: Vacinas Bacterianas/classificação
Neisseria meningitidis/imunologia
Meningite Meningocócica/epidemiologia
Meningite Meningocócica/prevenção & controle
Vacinação
Limites: Seres Humanos
Criança
Adulto
Responsável: BR11.1 - Biblioteca


  7 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Camacho, Luiz Antonio Bastos
Texto completo
Id: biblio-990193
Autor: Santos, Eliane Matos dos; Noronha, Tatiana Guimarães; Alves, Isabelle Soares; Cruz, Robson Leite de Souza; Ferroco, Clara Lucy de Vasconcellos; Brum, Ricardo Cristiano; Oliveira, Patricia Mouta Nunes de; Siqueira, Marilda Mendonça; Lima, Mariza Cristina; Ramos, Francisco Luzio de Paula; Bragagnolo, Camila de Marco; Camacho, Luiz Antonio Bastos; Maia, Maria de Lourdes de Sousa.
Título: Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study
Fonte: Mem. Inst. Oswaldo Cruz;114:e180517, 2019. tab, graf.
Idioma: en.
Resumo: BACKGROUND Field testing required to license the combined measles, mumps, and rubella (MMR) vaccine must take into account the current recommendation of the vaccine in Brazil: first dose at 12 months and second dose at 15 months of age in combination with a varicella vaccine. OBJECTIVES This study aimed to evaluate the clinical consistency, immunogenicity, and reactogenicity of three batches of MMR vaccine prepared with active pharmaceutical ingredients (API) from Bio-Manguinhos, Fiocruz (MMR-Bio), and compare it to a vaccine (MMR produced by GlaxoSmithKline) with different API. METHODS This was a phase III, randomised, double-blind, non-inferiority study of the MMR-Bio administered in infants immunised at health care units in Pará, Brazil, from February 2015 to January 2016. Antibody levels were titrated by immunoenzymatic assays. Adverse events were recorded in diaries. FINDINGS Seropositivity levels after MMR-Bio were 97.6% for measles, 84.7% for mumps, and 98.0% for rubella. After the MMRV vaccine, seroconversion rates and GMT increased substantially for mumps. In contrast, approximately 35% of the children had no detectable antibodies to varicella. Systemic adverse events were more frequent than local events. CONCLUSION The demonstration of batch consistency and non-inferiority of the Bio-MMR vaccine completed the technology transfer. This is a significant technological achievement with implications for immunisation programs.
Descritores: Rubéola (Sarampo Alemão)
Vacinas Bacterianas/provisão & distribuição
Imunogenicidade da Vacina/imunologia
Vírus do Sarampo
-Ensaio Clínico
Limites: Seres Humanos
Responsável: BR1.1 - BIREME


  8 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-281815
Autor: Hospital de Pediatría Prof. Dr. Juan P. Garrahan. Servicio de Control Epidemiológico e Infectología.
Título: ¿Vacuna antimeningococcica B? / A group B meningoccocal vaccine?
Fonte: Med. infant;1(2):88-88, nov. 1993.
Idioma: es.
Descritores: Vacinas Bacterianas
Meningite/prevenção & controle
Meningite Meningocócica/prevenção & controle
-Argentina
Cuba
Limites: Seres Humanos
Masculino
Feminino
Pré-Escolar
Adolescente
Adulto
Responsável: AR305.1 - SID - Servicio de Información y Documentación


  9 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-769835
Autor: Forster, Karine M; Hartwig, Daiane D; Oliveira, Thaís L; Bacelo, Kátia L; Schuch, Rodrigo; Amaral, Marta G; Dellagostin, Odir A.
Título: DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis
Fonte: Mem. Inst. Oswaldo Cruz;110(8):989-995, Dec. 2015. tab, graf.
Idioma: en.
Resumo: Leptospirosis is a zoonotic disease caused by pathogenic spirochetes of theLeptospira genus. Vaccination with bacterins has severe limitations. Here, we evaluated the N-terminal region of the leptospiral immunoglobulin-like B protein (LigBrep) as a vaccine candidate against leptospirosis using immunisation strategies based on DNA prime-protein boost, DNA vaccine, and subunit vaccine. Upon challenge with a virulent strain ofLeptospira interrogans, the prime-boost and DNA vaccine approaches induced significant protection in hamsters, as well as a specific IgG antibody response and sterilising immunity. Although vaccination with recombinant fragment of LigBrep also produced a strong antibody response, it was not immunoprotective. These results highlight the potential of LigBrep as a candidate antigen for an effective vaccine against leptospirosis and emphasise the use of the DNA prime-protein boost as an important strategy for vaccine development.
Descritores: Antígenos de Bactérias/imunologia
Proteínas de Bactérias/imunologia
Vacinas Bacterianas/imunologia
Leptospira/imunologia
Leptospirose/prevenção & controle
Vacinação/métodos
-Adjuvantes Imunológicos
Biópsia
Cercopithecus aethiops
Sequência Conservada
Ensaio de Imunoadsorção Enzimática
Imunidade Humoral/imunologia
Imunoglobulina A/genética
Imunoglobulina A/imunologia
Imunoglobulina G/imunologia
Imunoglobulinas/genética
Imunoglobulinas/imunologia
Rim/patologia
Leptospirose/imunologia
Pulmão/patologia
Mesocricetus
Análise de Sobrevida
Células Vero
Vacinas de DNA/imunologia
Vacinas Sintéticas/imunologia
Vacinas Sintéticas/microbiologia
Limites: Animais
Cricetinae
Feminino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  10 / 159 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-741261
Autor: Silva, Adilson José da; Zangirolami, Teresa Cristina; Novo-Mansur, Maria Teresa Marques; Giordano, Roberto de Campos; Martins, Elizabeth Angélica Leme.
Título: Live bacterial vaccine vectors: An overview
Fonte: Braz. j. microbiol;45(4):1117-1129, Oct.-Dec. 2014. tab.
Idioma: en.
Resumo: Genetically attenuated microorganisms, pathogens, and some commensal bacteria can be engineered to deliver recombinant heterologous antigens to stimulate the host immune system, while still offering good levels of safety. A key feature of these live vectors is their capacity to stimulate mucosal as well as humoral and/or cellular systemic immunity. This enables the use of different forms of vaccination to prevent pathogen colonization of mucosal tissues, the front door for many infectious agents. Furthermore, delivery of DNA vaccines and immune system stimulatory molecules, such as cytokines, can be achieved using these special carriers, whose adjuvant properties and, sometimes, invasive capacities enhance the immune response. More recently, the unique features and versatility of these vectors have also been exploited to develop anti-cancer vaccines, where tumor-associated antigens, cytokines, and DNA or RNA molecules are delivered. Different strategies and genetic tools are constantly being developed, increasing the antigenic potential of agents delivered by these systems, opening fresh perspectives for the deployment of vehicles for new purposes. Here we summarize the main characteristics of the different types of live bacterial vectors and discuss new applications of these delivery systems in the field of vaccinology.
Descritores: Vacinas Bacterianas/imunologia
Portadores de Fármacos
-Infecções Bacterianas/prevenção & controle
Vacinas Bacterianas/genética
Neoplasias/terapia
Organismos Geneticamente Modificados/genética
Organismos Geneticamente Modificados/imunologia
Vacinas Atenuadas/genética
Vacinas Atenuadas/imunologia
Limites: Animais
Seres Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME



página 1 de 16 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde